Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858091 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPTKDM4EDRD4DRD2 | |
| SCHEMBL6263381 | 0.85 | DRD4 (0.70) | ALDH1A1MAPTKDM4EPRMT6DRD4 | |
| SCHEMBL27662780 | 0.82 | AGXT (0.56) | ALDH1A1MAPTPRMT6DRD4DRD2 | |
| SCHEMBL2376462 | 0.81 | CHRNA7 (0.59) | MAPTKDM4EPRMT6DRD4DRD2 | |
| SCHEMBL6865778 | 0.80 | KDM4E (0.67) | ALDH1A1MAPTKDM4ETSHRHTR7 | |
| SCHEMBL15938014 | 0.80 | HTR7 (0.67) | ALDH1A1MAPTKDM4EDRD4DRD2 | |
| SCHEMBL4453962 | 0.78 | LOXL2 (0.64) | ALDH1A1MAPTTSHRHTR7 | |
| SCHEMBL15829997 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4EPRMT6DRD4 | |
| SCHEMBL109344 | 0.77 | AGXT (0.69) | ALDH1A1MAPTKDM4EPRMT6KCNH2 | |
| SCHEMBL6031187 | 0.77 | ALDH1A1 (0.77) | ALDH1A1MAPTKDM4EDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 2676/4885MAPT 2949/4885KDM4E 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.